Dupixent® (dupilumab) approved in Egypt for adults and adolescents 12 years and older with moderate-to-severe Atopic Dermatitis &  severe Asthma by the Egyptian Drug Authority

Egypt is the 1st country in Africa approved Dupixent  for moderate -to - severe Atopic Dermatitis & severe Asthma

Dupixentreg; (dupilumab) approved in Egypt for adults and adolescents 12 years and older with moderate-to-severe Atopic Dermatitis nbsp;severe Asthma by the Egyptian Drug Authority

Dupixent included in Egypt' s list approved drug that meet urgent clinical need.

Cairo Egypt –  The Egyptian Drug Authority - EDA  in Egypt  has approved Dupixent® (dupilumab) in adults & adolescents  12 years and older  for 2 chronic diseases : As a treatment of moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and as an add-on maintenance treatment for severe asthma with type 2 inflammation

"Today's approval marks a significant profound impact on the lives of people with moderate-to-severe atopic dermatitis & severe asthma  for adults and adolescents," said Ahmed Hegazy General Manager Sanofi Genzyme in Egypt

He added, “The absence treatment for moderate-to-severe atopic dermatitis has left many patients and their caregivers for them coping with the physical and emotional burden of the disease,”

"Furthermore, people whose severe asthma is inadequately controlled on current therapy continue to have trouble breathing and suffer potentially life-threatening exacerbations. These daily burdens can significantly diminish quality of life, causing missed days of school, work and social activities,


Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases